These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 917456)

  • 41. [Results in the use of immunochemotherapy in patients with cutaneous malignant melanoma].
    Calbo L; Gorgone S; Palmeri R; Salibra M; Melita P
    Chir Ital; 1983 Aug; 35(4):519-25. PubMed ID: 6680859
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Malignant melanoma.
    Spitler LE
    J Invest Dermatol; 1976 Sep; 67(3):435-41. PubMed ID: 787436
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Immunotherapy of malignant melanomas].
    Macher E
    Haematol Blood Transfus; 1978; 21():285-91. PubMed ID: 738638
    [No Abstract]   [Full Text] [Related]  

  • 44. BCG stimulation of immune responsiveness in patients with malignant melanoma. Preliminary report.
    Gutterman J; Mavligit G; McBride C; Frei E; Hersh EM
    Cancer; 1973 Aug; 32(2):321-7. PubMed ID: 4722915
    [No Abstract]   [Full Text] [Related]  

  • 45. Immunotherapy of human malignant melanoma with oil-attached BCG cell-wall skeleton.
    Yamamura Y; Yoshizaki K; Azuma I; Yagura T; Watanabe T
    Gan; 1975 Aug; 66(4):355-63. PubMed ID: 1102379
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Critical analysis of treatment of stage II and stage III melanoma patients with immunotherapy.
    Jewell WR; Thomas JH; Sterchi JM; Morse PA; Humphrey LJ
    Ann Surg; 1976 May; 183(5):543-9. PubMed ID: 776107
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro assay of cell-mediated immunity in BCG therapy of malignant melanoma: a preliminary report.
    Nathanson L; Clark DA
    Natl Cancer Inst Monogr; 1973 Dec; 39():221-4. PubMed ID: 4595321
    [No Abstract]   [Full Text] [Related]  

  • 48. Common human melanoma membrane antigens detected by mixed hemadsorption microassay with serum from a patient undergoing immunotherapy with autologous tumor cells.
    Liao SK; Leong SP; Sutherland CM; Dent PB; Kwong PC; Krementz ET
    Cancer Res; 1978 Dec; 38(12):4395-400. PubMed ID: 82477
    [No Abstract]   [Full Text] [Related]  

  • 49. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line.
    Waanders GA; Rimoldi D; Liénard D; Carrel S; Lejeune F; Dietrich PY; Cerottini JC; Romero P
    Clin Cancer Res; 1997 May; 3(5):685-96. PubMed ID: 9815737
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Demonstration of lymphocyte blastogenesis--inhibiting factors in sera of melanoma patients.
    Rangel DM; Golub SH; Morton DL
    Surgery; 1977 Aug; 82(2):224-32. PubMed ID: 877866
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The use of oral BCG in the treatment or metastatic malignant melanoma.
    Pritchard KI; Cowan DH; Baker MA; Osoba D; Phillips RA; Clark DA
    Med Pediatr Oncol; 1976; 2(2):173-81. PubMed ID: 785199
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Results of adjuvant BCG immunotherapy in malignant melanoma.
    Wätzig V; Knopf B
    Arch Geschwulstforsch; 1981; 51(6):493-6. PubMed ID: 7332442
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BCG immunotherapy in previously treated malignant melanoma patients.
    Mujagić H; Kolarić K; Malenica B; Nola P
    Biomedicine; 1979 Jun; 30(2):95-102. PubMed ID: 476270
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide.
    Berd D; Mastrangelo MJ
    Cancer Invest; 1988; 6(3):337-49. PubMed ID: 3167614
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effectiveness of systemic BCG therapy in advanced melanoma.
    El-Domeiri AA; Nika B; Hsia WC; Crispen R; Sabet TY; Gupta TK
    Arch Surg; 1977 Mar; 112(3):257-9. PubMed ID: 843215
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adjuvant immunotherapy with BCG in stage II malignant melanoma.
    Byrne MJ; Van Hazel G; Reynolds PM; Lemish WM; Holman CD
    J Surg Oncol; 1983 Jun; 23(2):114-6. PubMed ID: 6343725
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunopathologic changes in patients with cutaneous malignant melanoma following intratumoral inoculation BCG: correlation with cell-mediated immunity.
    Lieberman R; Epstein W; Fudenberg HH
    Int J Cancer; 1974 Sep; 14(3):401-16. PubMed ID: 4617711
    [No Abstract]   [Full Text] [Related]  

  • 58. [Intranodular treatment with BCG of cutaneous and subcutaneous metastases of malignant melanoma (author's transl)].
    Balzarini GP; Cascinelli N; Fontana V; Veronesi U
    Tumori; 1974; 60(4):345-52. PubMed ID: 4439501
    [No Abstract]   [Full Text] [Related]  

  • 59. [Activity of 2,4 dinitrochlorbenzene skin tests during the course of immunotherapy of malignant melanomas].
    Richter J; Duchková H; Kubíková M
    Cas Lek Cesk; 1975 Sep; 114(39):1201-3. PubMed ID: 1182748
    [No Abstract]   [Full Text] [Related]  

  • 60. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
    Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
    J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.